Reduced radioiodine uptake at increased iodine intake and 131I-induced release of "cold" iodine stored in the thyroid

NuklearMedizin

Volumn 44, Issue 4, 2005, Pages 137-142

  Meller, Birgit ^a   Haase, A ^a   Seyfarth, M ^a   Wenzel, B E ^a   Richter, E ^a   Baehre, M ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Radioiodine therapy; Thyroglobulin; Urinary iodine excretion

Indexed keywords

ANTITHYROID AGENT; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; THYROXINE; IODINE;

ARTICLE; BLOOD SAMPLING; DISEASE EXACERBATION; DRUG UPTAKE; HUMAN; HYPERTHYROIDISM; IODINE 131 UPTAKE TEST; LABORATORY TEST; MAJOR CLINICAL STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID DISEASE; THYROID GLAND; THYROID SCINTISCANNING; URINARY EXCRETION; DRUG EFFECT; METABOLISM; URINE;

HUMANS; IODINE; IODINE RADIOISOTOPES; THYROGLOBULIN; THYROID GLAND; THYROXINE;

EID: 23944487251     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625756     Document Type: Article

References (37)

1. 99mTc-pertechnetate. Acta Endocrinol (Cop) 1987; 115: 175-82.
2. Baehre M, Luig H, Emrich D et al. Improved quality and information in thyroid scintigraphy. Eur J Nucl Med 1985; 11: 194-7.
3. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-60.
4. Dederichs B, Otte R, Klink JE et al. Volume reduction of the thyroid after radioiodine therapy in patients with autonomous goiter and Basedow's goiter. Nuklearmedizin 1996; 35: 164-9.
5. Dietlein M, Dressler J, Grünwald F et al. Guideline for radioiodine therapy for benign thyroid diseases (version 3). Nuklearmedizin 2004; 43: 217-20.
6. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for thyroid scintigraphy (version 2). Nuklearmedizin 2003; 42: 120-2.
7. Eng PH, Cardona GR, Previti MC et al. Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol 2001; 144: 139-44.
8. Eng PH, Cardona GR, Fang SL et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999; 140: 3404-10.
9. +/I-symporter. Mechanism, stoichiometry, and specificity. J Biol Chem 1999; 272: 27230-8.
10. 125I uptake competing with iodine absorption by the thyroid gland following povidone-iodine skin application Exp Anim 1997; 46: 197-202.
11. 131I treatment of hyperthyroidism. Ann Intern Med 1972; 76: 721-3.
12. Grollman EF, Smolar A, Ommaya A et al. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 1986; 118: 2477-82.
13. Haase A, Baehre M, Lauer I et al. Radioiodine therapy of Graves' disease: Determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 2000; 108: 133-7.
14. Hampel R, Kuhlberg T, Zollner H et al. Aktueller Stand der alimentären lodversorgung in Deutschland. Z Ernährungswiss 1996; 35: 2-5.
15. 123I. Eur J Nucl Med Mol Imaging 2002; 29: 783-8.
16. Izumi M, Kubo I, Taura M et al. Kinetic study of immunoreactive human thyroglobulin. J Clin Endocrinol Metab 1986; 62: 410-2.
17. Izumi M, Larsen PR. Correlation of sequential changes in serum thyroglobulin, triiodthyronine, and thyroxine in patients with Graves' disease and subacute thyroiditis. Metabolism 1978; 27: 449-60.
18. 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med 1999, 55: 215-21.
19. Kreisig T, Abenhardt W, Mann K et al. Frühveränderungen der Schilddrüsenhormone nach Radiojodtherapie der Hyperthyreose unter Berücksichtigung von Ätiologie und begleiten- der Medikation. Klin Wochenschr 1989; 67: 386-92.
20. 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45: 619-25.
21. LeMoli, R, Wesche MFT, Tiel-van Buul MMC et al. Determinations of longterm outcome of radioiodine therapy of sporadic non-toxic goiter. Clin Endocrinol 1999; 50: 783-9.
22. Loeffler M, Weckesser M, Franzius C et al. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 240-3.
23. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol 1948; 59: 260-81.
24. McDermott MT, Kidd GS, Dodson Jr LE et al. Radioiodine-induced thyroid storm. Am J Med 1983; 75: 353-9.
25. Meller B, Lauer I, Baehre M et al. Influence of radioiodine therapy on urinary iodine excretion. Nuklearmedizin 1998; 37: 107-12.
26. Neubert A, Manz F, Remer T. Iodmonitoring bei Kindern: Iod-Kreatinin-Quotient versus lodkonzentration im Urin. In: Reiners C, Weinheimer B (Hsg). Schilddrüse 1997. Berlin, New York: de Gruyter 1998: 181-8.
27. Nygaard B, Hegedüs L, Nielsen KG et al. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol 1999; 50: 197-202.
28. Peters H, Fischer C, Bogner U et al. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism. Eur J Clin Investigation 1996; 26: 59-63.
29. 131I therapy in Graves' patients pretreated or not with methimazole. Nuklearmedizin 2004; 43: 129-34.
30. 131I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43: 828-34.
31. Reiners C. Radiojodtherapie. Dt Ärzteblatt 1993; 90: 2996-3003.
32. Riggs DS. Elevation of serum protein bound iodine after large doses of radioactive iodine. Fed Prod 1948; 7: 251-4.
33. 131I therapy and radioiodine kinetics. Nuklearmedizin 1996; 35: 175-80.
34. Tamagna EI, Levine GA, Hershman JM. Thyroid-hormone concentrations after radioiodine therapy for hyperthyroidism J Nucl Med 1979; 20: 387-91.
35. Wawschinek O, Eber O, Petek W et al. Bestimmung der Harniodausscheidung mittels einer modifizierten Cer-Arsenitmethode. Berichte der ÖGKC 1985; 8: 13-5.
36. Weber K, Wellner U, Voth E et al. Influence of stable iodine on the uptake of the thyroid-model versus experiment. Nuklearmedizin 2001; 40: 31-7.
37. 131I uptake of the thyroid gland - a model calculation. Nuklearmedizin 1996; 35: 251-63.